Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $23.5 million.

  • Keros Therapeutics' Non-Current Assets fell 1377.04% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year increase of 518.12%. This contributed to the annual value of $27.0 million for FY2024, which is 1874.45% up from last year.
  • As of Q3 2025, Keros Therapeutics' Non-Current Assets stood at $23.5 million, which was down 1377.04% from $24.4 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Non-Current Assets peaked at $27.2 million during Q3 2024, and registered a low of $1.7 million during Q1 2021.
  • In the last 5 years, Keros Therapeutics' Non-Current Assets had a median value of $22.0 million in 2023 and averaged $16.2 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 1485.63% in 2021, then soared by 46639.47% in 2023.
  • Keros Therapeutics' Non-Current Assets (Quarter) stood at $3.8 million in 2021, then soared by 451.4% to $21.0 million in 2022, then grew by 8.18% to $22.7 million in 2023, then grew by 18.74% to $27.0 million in 2024, then decreased by 13.03% to $23.5 million in 2025.
  • Its Non-Current Assets stands at $23.5 million for Q3 2025, versus $24.4 million for Q2 2025 and $25.1 million for Q1 2025.